ProShare Advisors
RPTX

ProShare Advisors’s Repare Therapeutics RPTX Stock Holding History

ProShare Advisors’s Portfolio RPTX Stock Details RPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-7,929
Closed -$208K – 2348
2021
Q3 		$208K Buy
7,929
+1,280
+19% +$41.3K ﹤0.01% 1774
2021
Q2 		$207K Buy
+6,649
New +$218K ﹤0.01% 2125

Other funds holding RPTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

ProShare Advisors's RPTX Position: Q4 2021 in Review

ProShare Advisors sold out of Repare Therapeutics (RPTX) in Q4 2021, closing a stake of 7,929 shares — an estimated $208K sold.

ProShare Advisors first reported a position in RPTX in Q2 2021 and held it in 2 quarters. The position peaked at $208K in Q3 2021. 67 funds tracked by Wall St. Rank hold RPTX as of Q4 2021.

  • ProShare Advisors reported no remaining Repare Therapeutics position as of Q4 2021 after selling out during the quarter.
  • ProShare Advisors sold 7,929 Repare Therapeutics shares in Q4 2021, an estimated $208K.
  • ProShare Advisors first reported a position in Repare Therapeutics in Q2 2021 and held it in 2 quarters.
  • ProShare Advisors's Repare Therapeutics position peaked at $208K in Q3 2021.
  • 67 funds tracked by Wall St. Rank held Repare Therapeutics as of Q4 2021.

Based on ProShare Advisors's 13F filing for Q4 2021, filed 8 Feb 2022.